Haemonetics (NYSE:HAE – Get Free Report) had its price target boosted by equities researchers at Citigroup from $79.00 to $92.00 in a research report issued on Friday,Benzinga reports. Citigroup’s price target would suggest a potential upside of 5.14% from the stock’s current price. Finally, Robert W. Baird set a $96.00 price target on Haemonetics in a research report on Friday. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average target price of $90.89. BTIG price target reportThe new target implies additional upside from current levels, reinforcing the bullish view following the earnings release.